Real-time enrollment status for this pik3ca mutation clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 1:42 PM UTC
| NCT Number | NCT05216432 |
| Recruiting Status | Recruiting |
| Condition | PIK3CA Mutation |
| Phase | PHASE1 |
| Target Enrollment | 930 participants |
| Active Locations | 24 sites in the US |
| Sponsor | Relay Therapeutics, Inc. |
| Last Updated on CT.gov | September 22, 2025 (Sep 22, 2025) |
As of October 12, 2026: Clinical trial NCT05216432 is currently recruiting participants. This phase1 study for pik3ca mutation is actively seeking new participants at 24 locations across the United States. The study is sponsored by Relay Therapeutics, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT05216432 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 24 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT05216432 was last updated Sep 22, 2025 (September 22, 2025). HelloStudys verifies this status automatically.